This disconnect between clinical efficacy and real-world utilization remains one of the most persistent challenges in lipid management.
Joshua Wyatt
Advertisement
Joshua Wyatt is a senior business analyst at Lifescience Dynamics.
Articles by Joshua Wyatt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
5